Reply to the Editor  by Gerosa, Gino et al.
Walter Eichinger reports lecture fees from Ed-
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Reply to the Editor:
We appreciate the comments of Eichinger,
Hettich, and Lange on our recent article
reporting on in vitro performances of 5
different aortic tissue valves designed for
supra-annular implantation.1
We agree that the complex aortic root
anatomy is responsible for different find-
ings and different prosthesis fittings, be-
cause larger sewing rings and higher pro-
files may play a crucial role in terms of
encumbrance in the sinus portion of the
aorta. We selected the largest prostheses of
each model that could be fitted in a 21-mm
valve holder regardless of the manufactur-
er’s size. We observed that the valves with
the more advantageous ratio between inter-
nal orifice versus tissue annulus–sewing
ring diameters were the Sorin Mitroflow
(Sorin Biomedica Spa, Saluggia, Italy) and
the Carpentier-Edwards Magna bioprosthe-
ses (Edwards Lifesciences, Irvine, Calif).
Unfortunately, the Mitroflow valve has not
been studied by Eichinger, Hettich, and
Lange. Nevertheless, comparing the hydro-
dynamic performances of the Sorin Soprano
versus the Carpentier-Edwards Magna, we
did not observe significant differences be-
tween the two valves, such as those observed
by this group in vivo.2 Eichinger’s group
highlights the beneficial ratio between inter-
nal and sewing ring diameters as well
as the hemodynamic performances of the
Carpentier-Edwards Magna valve. In vivo,
the beneficial effect was observed only when
comparing patients with a larger tissue annu-
lus diameter (between 21 and 23 mm); sur-
prisingly, this benefit disappeared for the
smaller diameters (18-20 mm). We believe
that the beneficial ratio between internal ori-
fice diameter and sewing ring diameter is
valid also for 19- or 21-mm prostheses and
not only for the larger prosthesis sizes. More-
over, since the upsizing of the Medtronic
Mosaic (Medtronic, Inc, Minneapolis, Minn)
versus the Carpentier-Edwards Magna pros-
thesis was not possible in our in vitro study,
we maintain that the hemodynamic benefit,
observed in vivo with the Carpentier-
Edwards prosthesis in comparison with the
Medtronic Mosaic by Eichinger and coau-
thors,3 results mostly from the different in-
ternal orifice diameters and tissue annulus
diameters rather than from the prosthesis up-
Figure 1. The schematic drawing shows two aortic root anatomies with an identical tissue annulus diameter
(TAD). The right figure shows a more bulbar-shaped root. This is the ideal situation for complete supra-annular
placement, in which the TAD corresponds to the internal orifice diameter (IOD) of the prosthesis (TAD  IOD). The
left figure shows a narrow aortic root. Despite the same TAD, a completely supra-annular valve of the same size
(gray) would not fit in. Thus a smaller valve (white) has to be chosen with the consequence that, despite implanting
a completely supra-annular prosthesis, stent and sewing ring material impair the bloodstream. Thus the shape of
the aortic root does not allow the implantation of a valve large enough to ensure that the IOD corresponds to the
TAD. This illustrates the hypothesis that hemodynamic benefit cannot be achieved in every aortic root because of
a completely supra-annular placement of the prosthesis. ESRD, External sewing ring diameter.
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sizing,4 as observed in our in vitro compari-
son.1 Moreover, considering the excessively
and surprisingly high regurgitant volumes
observed in vitro with the Carpentier-
Edwards Magna valve, as well as the mini-
mal tolerability of this valve to stent distor-
tion, according to present work and to other
experiences in the literature,5,6 the upsizing
of the Carpentier-Edwards Magna should be,
to our mind, carefully considered.
Unfortunately, “in vivo” comparisons
between different prostheses are difficult
and misleading; several confounding fac-
tors, such as blood viscosity (patient he-
matocrit), heart rate, left ventricle and mi-
tral valve pattern, cardiac output, septum
hypertrophy, systemic hypertension, re-
duced systemic arterial compliance, and ef-
fects of angiotensin-converting enzyme in-
hibitors in hypertensive patients, data that
are rarely reported in clinical studies, are
frequently present. These factors may con-
found the data obtained by echocardio-
graphic studies. Other important factors
such as aortic root anatomy or variability in
surgical skill and implant technique might
indeed affect clinical comparisons. Finally,
echocardiography parameters (ie, effective
orifice area calculated by using the conti-
nuity equation) have inherent variability
that is mainly related to the techniques used
for its measurement, as well as to flow
dependency. For these reasons, we main-
tain that it is hazardous to conclude that a
prosthesis model is the gold standard by
interpreting only clinical results.
The system that we have used has a
virtually rigid arrangement section down-
stream from the aortic valve, which repre-
sents perhaps the single largest distortion
from reality. Attachment of a small com-
pliant device to the downstream section
could give a significantly different system
performance, mimicking an in vivo setting
such as an aorta setting. However, if we
compare two heart valves in this modified
system, we would expect to appreciate the
same differences between the two different
valves. Therefore, the pulse duplicator de-
vice is not really designed to give an accu-
rate representation of the true anatomy;
rather, it is a system that provides an ex-
traordinary and unquestionable bench test
for comparison of different prostheses.
The most striking finding of our study
was the ability to obtain a unique hydrody-
namic comparison of different models of su-
pra-annular tissue valves fitting a 21-mm di-
ameter artificial aortic annulus, regardless of
the labeled manufacturers’ size. This com-
parison can be helpful in assisting surgeons’
decisions.
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Nitric oxide precursors and
congenital cardiac surgery: A
randomized controlled trial of oral
citrulline. Definition of pulmonary
hypertension in Fontan circulation?
To the Editor:
We read with great interest the article
from Smith and colleagues1 describing
the effect of citrulline supplementation in
reducing postoperative pulmonary hyper-
tension. This is very appealing therapy
because it is reported to be effective and
without any side effects.
Nevertheless, we have a concern with
the definition of pulmonary hypertension.
The authors have used the accepted defini-
tion of pulmonary hypertension as a mean
pulmonary arterial pressure of at least 25
mm Hg2 or exceeding 50% of the mean
systemic artery pressure. Although accept-
able for patients presenting with ventricular
or atrioventricular septal defect, as well as
transposition of the great arteries, this def-
inition is more questionable for bidirec-
tional Glenn and Fontan procedures.
A prerequisite for a successful bidirec-
tional Glenn or Fontan procedure would be
a mean pressure of less than 15 mm Hg. In
addition, a pressure of more than 12 mm
Hg in a Fontan circulation would be con-
sidered a suboptimal result.
Taking 25 mm Hg as a limit to describe
high pulmonary pressure in this group in-
duces a significant bias to our point of
view. Assuming that we use 15 mm Hg as
the limit for the Glenn and Fontan group,
all patients (11/11) presented with pressure
of more than 15 mm Hg in the placebo
group, and 9 of 10 patients presented with
this pressure in the citrulline group. Taking
20 mm Hg as a superior limit, 4 of 11 in the
placebo group presented with pressure over
the limit compared with 4 of 10 in the
citrulline group, respectively.
On this basis, we think that groups with
shunt lesions and biventricular repair ver-
sus single-ventricle physiology should not
be evaluated similarly with regard to pul-
monary hypertension.
Another concern, and this is applicable to
both shunt lesions or single-ventricle circula-
tion, is that nothing is reported with regard to
postoperative care, and several confounding
factors can increase or decrease pulmonary
arterial pressures in this period, such as pH,
PO2, sedation, ventricular function, pulmo-
nary wedge or atrial pressures, and inotropic/
vasodilatory support for 48 hours.3
We think these points are of major im-
portance because citrulline levels might not
have been the sole responsible variable for
reducing pulmonary arterial pressure.
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